Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Platelet-driven remodeling of cancer cell glycoproteins fuels inflammation and metastasis
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
This study explores the crucial role of abnormal O- and N-glycosylation (modification of sugar molecules attached to proteins) in cancer progression and metastatic spread. It examines the effect of this deregulation at several stages of tumor development: primary tumor, microenvironment, blood circulation, and extravasation. During most of these stages, cancer cells can interact with platelets. Platelets are no longer simply coagulation agents but entities capable of educating cancer cells by modifying their enzymatic and transcriptional landscape. The possible use of a specific glycoprotein as a biomarker and a glycan common to several cancers as a therapeutic target has also been described.
Downloads
Download data is not yet available.
Citations
1. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell 2017;168:670-91. DOI: https://doi.org/10.1016/j.cell.2016.11.037
2. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70:5649-69. DOI: https://doi.org/10.1158/0008-5472.CAN-10-1040
3. Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling. Cancer Lett 2019;442:320-32. DOI: https://doi.org/10.1016/j.canlet.2018.10.015
4. Provenzano PP, Eliceiri K, Campbell JM, et al. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006;4:38. DOI: https://doi.org/10.1186/1741-7015-4-38
5. Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007;9:1392-400. DOI: https://doi.org/10.1038/ncb1658
6. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther 2012;11:257-66. DOI: https://doi.org/10.1158/1535-7163.MCT-11-0340
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. DOI: https://doi.org/10.1016/S0092-8674(00)81683-9
8. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. Genes Cancer 2011;2:1097-105. DOI: https://doi.org/10.1177/1947601911423031
9. Crinò L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev 2014;23:79-91. DOI: https://doi.org/10.1183/09059180.00008913
10. Loizzi V, Del Vecchio V, Gargano G, et al. Biological pathways involved in tumor angiogenesis and bevacizumab based anti-angiogenic therapy with special references to ovarian cancer. Int J Mol Sci 2017;18:1967. DOI: https://doi.org/10.3390/ijms18091967
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI: https://doi.org/10.1016/j.cell.2011.02.013
12. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13. DOI: https://doi.org/10.1016/j.ccr.2009.01.001
13. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5. DOI: https://doi.org/10.1038/nature04808
14. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23. DOI: https://doi.org/10.1016/j.ccr.2008.12.018
15. Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol 2021;14:173. DOI: https://doi.org/10.1186/s13045-021-01187-y
16. Ng MSF, Kwok I, Tan L, et al. Deterministic reprogramming of neutrophils within tumors. Science 2024;383:eadf6493. DOI: https://doi.org/10.1126/science.adf6493
17. Aroca-Crevillén A, Vicanolo T, Ovadia S, Hidalgo A. Neutrophils in physiology and pathology. Annu Rev Pathol 2024;19:227-59. DOI: https://doi.org/10.1146/annurev-pathmechdis-051222-015009
18. Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 2019;16:601-20. DOI: https://doi.org/10.1038/s41571-019-0222-4
19. Jaillon S, Ponzetta A, Di Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer 2020;20:485-503. DOI: https://doi.org/10.1038/s41568-020-0281-y
20. Kalafati L, Hatzioannou A, Hajishengallis G, Chavakis T. The role of neutrophils in trained immunity. Immunol Rev 2023;314:142-57. DOI: https://doi.org/10.1111/imr.13142
21. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-8. DOI: https://doi.org/10.1056/NEJMc1203095
22. Li R, Ren M, Chen N, et al. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer 2014;14:167. DOI: https://doi.org/10.1186/1471-2407-14-167
23. Plantureux L, Mège D, Crescence L, et al. The interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis. Cancer Res 2020;80:291-303. DOI: https://doi.org/10.1158/0008-5472.CAN-19-1181
24. Le Chapelain O, Ho-Tin-Noé B. Intratumoral platelets: harmful or incidental bystanders of the tumor microenvironment? Cancers 2022;14:2192. DOI: https://doi.org/10.3390/cancers14092192
25. Wandall HH, Rumjantseva V, Tølbøll Sørensen Al, et al. The origin and function of platelet glycosyltransferases. Blood 2012;120:626-35. DOI: https://doi.org/10.1182/blood-2012-02-409235
26. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov 2022;12:31-46. DOI: https://doi.org/10.1158/2159-8290.CD-21-1059
27. Wu Y, Chen X, Wang S, Wang S. Advances in the relationship between glycosyltransferases and multidrug resistance in cancer. Clin Chim Acta 2019;495:417-21. DOI: https://doi.org/10.1016/j.cca.2019.05.015
28. Jin F, Wang F. The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins. Glycoconj J 2020;37:277-91. DOI: https://doi.org/10.1007/s10719-020-09912-4
29. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015;15:540-55. DOI: https://doi.org/10.1038/nrc3982
30. Cohen EN, Fouad TM, Lee B-N, et al. Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Res Treat 2019;176.545-56. DOI: https://doi.org/10.1007/s10549-019-05258-0
31. Trinchera M, Aronica A, Dall’Olio F. Selectin ligands sialyl-Lewis a and sialyl-Lewis x in gastrointestinal cancers. Biology 2017;6:16. DOI: https://doi.org/10.3390/biology6010016
32. Mereiter S, Balmaña M, Campos D, et al. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell 2019;36:6-16. DOI: https://doi.org/10.1016/j.ccell.2019.06.006
33. Dall’Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed) 2012;17:670-99. DOI: https://doi.org/10.2741/3951
34. Varki A. N-glycans. In: A. Varki (ed.) Essentials of Glycobiology. New York, Cold Spring Harbor Laboratory Press; 1999.
35. Nakano M, Mishra SK, Tokoro Y, et al. Bisecting GlcNAc is a general suppressor of terminal modification of N-glycan. Mol Cell Proteomics 2019;18:2044-57. DOI: https://doi.org/10.1074/mcp.RA119.001534
36. Pearce OMT. Cancer glycan epitopes: biosynthesis, structure and function. Glycobiology 2018;28:670-96. DOI: https://doi.org/10.1093/glycob/cwy023
37. Varki A. Essentials of glycobiology. New York, Cold Spring Harbor Laboratory Press; 1999.
38. Meezan E, Wu HC, Black PH, Robbins PW. Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry 1969;8:2518-24. DOI: https://doi.org/10.1021/bi00834a039
39. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med Berl Ger 2007;85:1301-7. DOI: https://doi.org/10.1007/s00109-007-0281-3
40. Belo AI, van Vliet SJ, Maus A, et al. Hypoxia inducible factor 1α down regulates cell surface expression of α1,2-fucosylated glycans in human pancreatic adenocarcinoma cells. FEBS Lett 2015;589:2359-66. DOI: https://doi.org/10.1016/j.febslet.2015.07.035
41. Greville G, Lop E, Huang C, et al. Hypoxia alters epigenetic and N-glycosylation profiles of ovarian and breast cancer cell lines in-vitro. Front Oncol 2020;10:1218. DOI: https://doi.org/10.3389/fonc.2020.01218
42. Lin M-C, Lin J-J, Hsu C-L, et al. GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness. Oncogene 2017;36:4243-52. DOI: https://doi.org/10.1038/onc.2017.8
43. Koike T, Kimura N, Miyazaki K, et al. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci USA 2004;101:8132-7. DOI: https://doi.org/10.1073/pnas.0402088101
44. Arriagada C, Silva P, Torres VA. Role of glycosylation in hypoxia-driven cell migration and invasion. Cell Adhes Migr 2018;13:13-22. DOI: https://doi.org/10.1080/19336918.2018.1491234
45. Trinchera M, Zulueta A, Caretti A, Dall’Olio F. Control of glycosylation-related genes by DNA Methylation: the intriguing case of the B3GALT5 gene and its distinct promoters. Biology 2014;3:484. DOI: https://doi.org/10.3390/biology3030484
46. Chakraborty AK, de Frietas Sousa, Chakraborty D, et al. GnT-V expression and metastatic phenotypes in macrophage-melanoma fusion hybrids is down-regulated by 5-Aza-dC: evidence for methylation sensitive, extragenic regulation of GnT-V transcription. Gene 2006;374:166-73. DOI: https://doi.org/10.1016/j.gene.2006.01.031
47. Ide Y, Miyoshi E, Nakagawa T, et al. Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem Biophys Res Commun 2006;341:478-82. DOI: https://doi.org/10.1016/j.bbrc.2005.12.208
48. Chachadi VB, Cheng H, Klinkebiel D, et al. 5-Aza-2′-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside α2,3-sialyltransferase 6 gene. Int J Biochem Cell Biol 2011;43:586-93. DOI: https://doi.org/10.1016/j.biocel.2010.12.015
49. Kawamura YI, Toyota M, Kawashima R, et al. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 2008;135:142-51. DOI: https://doi.org/10.1053/j.gastro.2008.03.031
50. Takamatsu S, Antonopoulos A, Ohtsubo K, et al. Physiological and glycomic characterization of N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice. Glycobiology 2010;20:485-97. DOI: https://doi.org/10.1093/glycob/cwp200
51. Hevey R, Ling C-C. Recent advances toward the development of inhibitors to attenuate tumor metastasis via the interruption of lectin-ligand interactions. Adv Carbohydr Chem Biochem 2013;69:125-207. DOI: https://doi.org/10.1016/B978-0-12-408093-5.00005-8
52. Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer 2021;1875:188464. DOI: https://doi.org/10.1016/j.bbcan.2020.188464
53. Luo Y, Cao H, Lei C, Liu J. ST6GALNAC1 promotes the invasion and migration of breast cancer cells via the EMT pathway. Genes Genomics 2023;45:1367-76. DOI: https://doi.org/10.1007/s13258-023-01445-y
54. Pinho SS, Matos AJF, Lopes C, et al. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression. BMC Cancer 2007;7:124. DOI: https://doi.org/10.1186/1471-2407-7-124
55. Guo H-B, Lee I, Kamar M, Pierce M. N-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. J Biol Chem 2003;278:52412-24. DOI: https://doi.org/10.1074/jbc.M308837200
56. Carvalho S, Catarino TA, Dias AM, et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene 2016;35:1619-31. DOI: https://doi.org/10.1038/onc.2015.225
57. Liu D, Gao Z, Yue L. Fucosyltransferase 8 deficiency suppresses breast cancer cell migration by interference of the FAK/integrin pathway. Cancer Biomark Sect Dis Markers 2019;25:303-11. DOI: https://doi.org/10.3233/CBM-190209
58. Liwosz A, Lei T, Kukuruzinska MA. N-glycosylation affects the molecular organization and stability of E-cadherin junctions. J Biol Chem 2006;281:23138-49. DOI: https://doi.org/10.1074/jbc.M512621200
59. Nita-Lazar M, Rebustini I, Walker J, Kukuruzinska MA. Hypoglycosylated E-cadherin promotes the assembly of tight junctions through the recruitment of PP2A to adherens junctions. Exp Cell Res 2010;316:1871-84. DOI: https://doi.org/10.1016/j.yexcr.2010.02.008
60. Dai Y, Liu L, Zeng T, et al. Overexpression of MUC13, a poor prognostic predictor, promotes cell growth by activating Wnt signaling in hepatocellular carcinoma. Am J Pathol 2018;188:378-91. DOI: https://doi.org/10.1016/j.ajpath.2017.10.016
61. Lahdaoui F, Messager M, Vincent A, et al. Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: implication of the Wnt/β-catenin pathway. Biochem J 2017;474:3733-46. DOI: https://doi.org/10.1042/BCJ20170348
62. Sengupta PK, Bouchie MP, Nita-Lazar M, et al. Coordinate regulation of N-glycosylation gene DPAGT1, canonical Wnt signaling and E-cadherin adhesion. J Cell Sci 2013;126:484-96. DOI: https://doi.org/10.1242/jcs.113035
63. Sengupta PK, Bouchie MP, Kukuruzinska MA. N-glycosylation gene DPAGT1 Is a target of the Wnt/β-catenin signaling pathway. J Biol Chem 2010;285:31164-73. DOI: https://doi.org/10.1074/jbc.M110.149195
64. Zhang J, Wang H, Wu J, et al. GALNT1 Enhances malignant phenotype of gastric cancer via modulating CD44 glycosylation to activate the Wnt/β-catenin signaling pathway. Int J Biol Sci 2022;18:6068-83. DOI: https://doi.org/10.7150/ijbs.73431
65. Che MI,Huang J, Hung JS, et al. β1, 4-N-acetylgalactosaminyltransferase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells. Oncotarget 2014;5:3673-84. DOI: https://doi.org/10.18632/oncotarget.1981
66. Lin MC, Chien PH, Wu HY, et al. C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer. Oncogene 2018;37:5780-93. DOI: https://doi.org/10.1038/s41388-018-0375-0
67. Wang Q, Liao C, Tan Z, et al. FUT6 inhibits the proliferation, migration, invasion, and EGF-induced EMT of head and neck squamous cell carcinoma (HNSCC) by regulating EGFR/ERK/STAT signaling pathway. Cancer Gene Ther 2023;30:182-91. DOI: https://doi.org/10.1038/s41417-022-00530-w
68. Hirakawa M, Takimoto R, Tamura F, et al. Fucosylated TGF-β receptors transduces a signal for epithelial-mesenchymal transition in colorectal cancer cells. Br J Cancer 2014;110:156-63. DOI: https://doi.org/10.1038/bjc.2013.699
69. Park S, Lim J-M, Chun JN, et al. Altered expression of fucosyltion pathway genes is associated with poor prognosis and tumor metastasis in non‑small cell lung cancer. Int J Oncol 2020;56:559-67. DOI: https://doi.org/10.3892/ijo.2019.4953
70. Kim Y-W, Park J, Lee H-J, et al. TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor. Biochem J 2012;445:403-11. DOI: https://doi.org/10.1042/BJ20111923
71. Tu C-F, Wu M-Y, Lin Y-C, et al. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. Breast Cancer Res 2017;19:111. DOI: https://doi.org/10.1186/s13058-017-0904-8
72. Lu J, Isaji T, Im S, et al. β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition. J Biol Chem 2014;289:34627-41. DOI: https://doi.org/10.1074/jbc.M114.593392
73. Partridge EA, Le Roy C, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004;306:120-4. DOI: https://doi.org/10.1126/science.1102109
74. Xu Q, Isaji T, Lu Y, et al. Roles of N-acetylglucosaminyltransferase III in epithelial-to-mesenchymal transition induced by transforming growth factor β1 (TGF-β1) in epithelial cell lines. J Biol Chem 2012;287:16563-74. DOI: https://doi.org/10.1074/jbc.M111.262154
75. Takeuchi H, Haltiwanger RS. Significance of glycosylation in Notch signaling. Biochem Biophys Res Commun 2014;453:235-42. DOI: https://doi.org/10.1016/j.bbrc.2014.05.115
76. Chabanais J, Labrousse F, Chaunavel A, et al. POFUT1 as a promising novel biomarker of colorectal cancer. Cancers 2018;10:411. DOI: https://doi.org/10.3390/cancers10110411
77. Dong S, Wang Z, Xiong W. POFUT1 promotes gastric cancer progression through Notch/Wnt dual signaling pathways dependent on the parafibromin-NICD1-β-catenin complex. J Chin Med Assoc 2023;86:806-17. DOI: https://doi.org/10.1097/JCMA.0000000000000957
78. Yuan Q, Chen X, Han Y, et al. Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway. Int J Cancer 2018;143:2319-30. DOI: https://doi.org/10.1002/ijc.31737
79. Nonaka M, Fukuda M. Expression and function of Poly-N-Acetyllactosamine Type glycans in cancer. In: Furukawa K, Fukuda M (eds.), Glycosignals in cancer: mechanisms of malignant phenotypes. Tokyo, Springer; 2016. pp. 141-61. DOI: https://doi.org/10.1007/978-4-431-55939-9_9
80. Dimitroff CJ. Galectin-binding O-glycosylations as regulators of malignancy. Cancer Res 2015;75:3195-202. DOI: https://doi.org/10.1158/0008-5472.CAN-15-0834
81. Okamoto T, Yoneyama MS, Hatakeyama S, et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol Med Rep 2013;7:359-64. DOI: https://doi.org/10.3892/mmr.2012.1189
82. Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol 2014;10:69-75. DOI: https://doi.org/10.1038/nchembio.1388
83. Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci Transl Med 2022;14:eabj1270. DOI: https://doi.org/10.1126/scitranslmed.abj1270
84. Vuagnat P, Champiat S. [Immunothérapies anti-checkpoints: aspects fondamentaux].[Article in French]. 2018. Available from: https://www.sfdiabete.org/files/files/JNDES/2019/1_mced95_vuagnat.pdf
85. Hsu J-M, Li C-W, Lai Y-J, Hung M-C. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res 2018;78:6349-53. DOI: https://doi.org/10.1158/0008-5472.CAN-18-1892
86. Wang Y-N, Lee H-H, Hsu JL, et al. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci 2020;27:77. DOI: https://doi.org/10.1186/s12929-020-00670-x
87. Huang Y, Zhang H-L, Li Z-L, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun 2021;12:2672. DOI: https://doi.org/10.1038/s41467-021-22618-x
88. Shan M, Yang D, Dou H, Zhang L. Chapter Four - Fucosylation in cancer biology and its clinical applications. In: Zhang L (ed.), Progress in molecular biology and translational science. Academic Press; 2019. pp. 93-119. DOI: https://doi.org/10.1016/bs.pmbts.2019.01.002
89. Chen W, Cheng Q, Li N, et al. The role of glycan-lectin interactions in the tumor microenvironment: immunosuppression regulators of colorectal cancer. Am J Cancer Res 2025;15:1347-83. DOI: https://doi.org/10.62347/WBJL4045
90. Janik ME, Przybyło M, Pocheć E, et al. Effect of alpha3beta1 and alphavbeta3 integrin glycosylation on interaction of melanoma cells with vitronectin. Acta Biochim Pol 2010;57:55-61. DOI: https://doi.org/10.18388/abp.2010_2372
91. Pocheć E, Bubka M, Rydlewska M, et al. Aberrant glycosylation of αvβ3 integrin is associated with melanoma progression. Anticancer Res 2015;35:2093-103.
92. Yoshimura M, Nishikawa A, Ihara Y, et al. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci USA 1995;92:8754-8. DOI: https://doi.org/10.1073/pnas.92.19.8754
93. Kariya Y, Oyama M, Hashimoto Y, et al. β4-integrin/PI3K signaling promotes tumor progression through the Galectin-3-N-glycan complex. Mol Cancer Res 2018;16:1024-34. DOI: https://doi.org/10.1158/1541-7786.MCR-17-0365
94. Yuan Y, Wu L, Shen S, et al. Effect of alpha 2,6 sialylation on integrin-mediated adhesion of breast cancer cells to fibronectin and collagen IV. Life Sci 2016;149:138-45. DOI: https://doi.org/10.1016/j.lfs.2016.02.071
95. Seales EC, Jurado GA, Brunson BA, et al. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 2005;65:4645-52. DOI: https://doi.org/10.1158/0008-5472.CAN-04-3117
96. Radhakrishnan P, Grandgenett PM, Mohr AM, et al. Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int J Cancer 2013;133:2824-33. DOI: https://doi.org/10.1002/ijc.28322
97. Kelm M, Lehoux S, Azcutia V, et al. Regulation of neutrophil function by selective targeting of glycan epitopes expressed on the integrin CD11b/CD18. FASEB J 2020;34:2326-43. DOI: https://doi.org/10.1096/fj.201902542R
98. Zen K, Cui L-B, Zhang C-Y, Liu Y. Critical role of mac-1 sialyl lewis x moieties in regulating neutrophil degranulation and transmigration. J Mol Biol 2007;374:54-63. DOI: https://doi.org/10.1016/j.jmb.2007.09.014
99. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009;19:507-14. DOI: https://doi.org/10.1016/j.sbi.2009.06.003
100. Carrascal MA, Silva Z, Crespo HJ, et al. Sialylation and dendritic cells: bridging innate and adaptive immune responses. In: Rauter AP, Lindhorst T (eds.), Carbohydrate chemistry. Roayl Society of Chemistry; 2011. pp. 94-116. DOI: https://doi.org/10.1039/9781849732765-00094
101. Jenner J, Kerst G, Handgretinger R, Müller I. Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells. Exp Hematol 2006;34:1212-8. DOI: https://doi.org/10.1016/j.exphem.2006.04.016
102. Videira PA, Amado IF, Crespo HJ, et al. Surface alpha 2-3- and alpha 2-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis. Glycoconj J 2008;25:259-68. DOI: https://doi.org/10.1007/s10719-007-9092-6
103. Radovani B, Gudelj I. N-Glycosylation and inflammation; the not-so-sweet relation. Front Immunol 2022;13:893365. DOI: https://doi.org/10.3389/fimmu.2022.893365
104. Palacios-Acedo A-L, Langiu M, Crescence L, et al. Platelet and cancer-cell interactions modulate cancer-associated thrombosis risk in different cancer types. Cancers 2022;14:730. DOI: https://doi.org/10.3390/cancers14030730
105. Gao S, Escalante C. Venous thromboembolism and malignancy. Expert Rev Anticancer Ther 2004;4:303-20. DOI: https://doi.org/10.1586/14737140.4.2.303
106. Plantureux L, Mège D, Crescence L, et al. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers 2018;10:441. DOI: https://doi.org/10.3390/cancers10110441
107. Girardi L, Wang T-F, Ageno W, Carrier M. Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism. Arterioscler Thromb Vasc Biol 2023;43:824-31. DOI: https://doi.org/10.1161/ATVBAHA.123.318779
108. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol 2023;41:3063-71. DOI: https://doi.org/10.1200/JCO.23.00294
109. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017;130:1499. DOI: https://doi.org/10.1182/blood-2017-03-743211
110. Palacios-Acedo AL, Mège D, CrescenceL, et al. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol 2019;10:1805. DOI: https://doi.org/10.3389/fimmu.2019.01805
111. Mezouar S, Frère C, Darbousset R, et al. Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res 2016;139:65-76. DOI: https://doi.org/10.1016/j.thromres.2016.01.006
112. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol 2018;11:125. DOI: https://doi.org/10.1186/s13045-018-0669-2
113. Mezouar S, Darbousset R, Dignat-George F, et al. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer 2015;136:462-75. DOI: https://doi.org/10.1002/ijc.28997
114. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles 2024;13:e12404. DOI: https://doi.org/10.1002/jev2.12451
115. Hisada Y, Ay C, Auriemma AC, et al. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost 2017;15:2208-17. DOI: https://doi.org/10.1111/jth.13809
116. Thomas GM, Brill A, Mezouar S, et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 2015;13:1310-9. DOI: https://doi.org/10.1111/jth.13002
117. Dudiki T, Veleeparambil M, Zhevlakova I, et al. Mechanism of tumor-platelet communications in cancer. Circ Res 2023;132:1447-61. DOI: https://doi.org/10.1161/CIRCRESAHA.122.321861
118. Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating Platelets as mediators of immunity, inflammation and thrombosis. Circ Res 2018;122:337-51. DOI: https://doi.org/10.1161/CIRCRESAHA.117.310795
119. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor–platelet interaction in solid tumors. Int J Cancer 2012;130:2747-60. DOI: https://doi.org/10.1002/ijc.27441
120. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011;20:576-90. DOI: https://doi.org/10.1016/j.ccr.2011.09.009
121. Sørensen AL, Hoffmeister KM, Wandall HH. Glycans and glycosylation of platelets: current concepts and implications for transfusion. Curr Opin Hematol 2008;15:606-11. DOI: https://doi.org/10.1097/MOH.0b013e328313e3bd
122. Lee-Sundlov MM, Stowell SR, Hoffmeister KM. Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells. J Thromb Haemost 2020;18:1535-47. DOI: https://doi.org/10.1111/jth.14874
123. Sørensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009;114:1645-54. DOI: https://doi.org/10.1182/blood-2009-01-199414
124. Hoffmeister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled blood platelets. Science 2003;301:1531-4. DOI: https://doi.org/10.1126/science.1085322
125. Jansen AJG, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbα metalloproteinase-mediated cleavage in mice. Blood 2012;119:1263-73. DOI: https://doi.org/10.1182/blood-2011-05-355628
126. Tribulatti MV, Mucci J, Van Rooijen N, et al. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas’ disease by reducing the platelet sialic acid contents. Infect Immun 2005;73:201-7. DOI: https://doi.org/10.1128/IAI.73.1.201-207.2005
127. Roka-Moiia Y, Lewis S, Cleveland E, et al. Shear stress promotes remodeling of platelet glycosylation via upregulation of platelet glycosidase activity: one more thing. Thromb Haemost 2025;125:317-36. DOI: https://doi.org/10.1055/a-2398-9532
128. Li J, Callum JL, Lin Y, et al. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica 2014;99:e61-e63. DOI: https://doi.org/10.3324/haematol.2013.102897
129. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015;6:7737. DOI: https://doi.org/10.1038/ncomms8737
130. Zhang Q, Huang M, Thomas ER, et al. The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives. Front Immunol 2024;15:1409461. DOI: https://doi.org/10.3389/fimmu.2024.1409461
131. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol 2012;13:448-62. DOI: https://doi.org/10.1038/nrm3383
132. Esko JD, Kimata K, Lindahl U. Chapter 16: Proteoglycans and sulfated glycosaminoglycans. in essentials of glycobiology. In: Varki A et al. (eds.) Essentials of glycobiology.New York, Cold Spring Harbor Laboratory Press; 2009.
133. Condac E, Dale GL, Bender-Neal D, et al. Xylosyltransferase II is a significant contributor of circulating xylosyltransferase levels and platelets constitute an important source of xylosyltransferase in serum. Glycobiology 2009;19:829-33. DOI: https://doi.org/10.1093/glycob/cwp058
134. Lee-Sundlov MM, Ashline DJ, Hannemann AJ, et al. Circulating blood and platelets supply glycosyltransferases that enable extrinsic extracellular glycosylation. Glycobiology 2017;27:188-98. DOI: https://doi.org/10.1093/glycob/cww108
135. Voss M. Proteolytic cleavage of Golgi glycosyltransferases by SPPL3 and other proteases and its implications for cellular glycosylation. Biochim Biophys Acta Gen Subj 2024;1868:130668. DOI: https://doi.org/10.1016/j.bbagen.2024.130668
136. Pan Y, Wang Y, Wang Y, et al. Platelet-derived microvesicles (PMVs) in cancer progression and clinical applications. Clin Transl Oncol 2023;25:873-81. DOI: https://doi.org/10.1007/s12094-022-03014-3
137. Langiu M, Crescence L, Mège D, et al. Consequences of platelet-educated cancer cells on the expression of inflammatory and metastatic glycoproteins. PloS One 2025;20:e0317096. DOI: https://doi.org/10.1371/journal.pone.0317096
138. Hall MK, Shajahan A, Burch AP, et al. Limited N-glycan processing impacts chaperone expression patterns, cell growth and cell invasiveness in neuroblastoma. Biology (Basel) 2023;12:293. DOI: https://doi.org/10.3390/biology12020293
139. Taniguchi N, Ohkawa Y, Maeda K, et al. True significance of N-acetylglucosaminyltransferases GnT-III, V and α1,6 fucosyltransferase in epithelial-mesenchymal transition and cancer. Mol Aspects Med 2021;9;100905. DOI: https://doi.org/10.1016/j.mam.2020.100905
140. Wu Y, Luo J, Li H, et al. B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma. Ann Transl Med 2022;10:295. DOI: https://doi.org/10.21037/atm-22-493
141. Zhang W, Hou T, Niu C, et al. B3GNT3 expression is a novel marker correlated with pelvic lymph node metastasis and poor clinical outcome in early-stage cervical cancer. PloS One 2015;10:e0144360. DOI: https://doi.org/10.1371/journal.pone.0144360
142. Tuccillo FM, de Laurentiis A, Palmieri C, et al. Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res Int 2014;2014:742831. DOI: https://doi.org/10.1155/2014/742831
143. Xu Y, Zhang P, Zhang K, Huang C. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188634. DOI: https://doi.org/10.1016/j.bbcan.2021.188634
144. Gao Y, Wang J, Zhou Y, et al. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep 2018;8:2732. DOI: https://doi.org/10.1038/s41598-018-21048-y
145. Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget 2016;7:35478-89. DOI: https://doi.org/10.18632/oncotarget.8155
146. Peixoto A, Relvas-Santos M, Azevedo R, et al. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front Oncol 2019;9:380. DOI: https://doi.org/10.3389/fonc.2019.00380
147. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics 2011;8:7. DOI: https://doi.org/10.1186/1559-0275-8-7
148. de Laurentiis A, Gaspari M, Palmieri C, et al. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. Mol Cell Proteomics 2011;10:M111.007898. DOI: https://doi.org/10.1074/mcp.M111.007898
149. Saldova R, Royle L, Radcliffe CM, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007;17:1344-56. DOI: https://doi.org/10.1093/glycob/cwm100
150. Sagar S, Leiphrakpam PD, Thomas D, et al. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Cancer Lett 2021;503:91-102. DOI: https://doi.org/10.1016/j.canlet.2021.01.015
151. Lumibao JC, Tremblay JR, Hsu J, Engle DD. Altered glycosylation in pancreatic cancer and beyond. J Exp Med 2022;219:e20211505. DOI: https://doi.org/10.1084/jem.20211505
152. Islam MK, Khan M, Gidwani K, et al. Lectins as potential tools for cancer biomarker discovery from extracellular vesicles. Biomark Res 2023;11:85. DOI: https://doi.org/10.1186/s40364-023-00520-6
153. Zhao J, Qiu W, Simeone DM, Lubman DM. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res 2007;6:1126-38. DOI: https://doi.org/10.1021/pr0604458
154. Alley WR Jr, Vasseur JA, Goetz JA, et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res 2012;11:2282-300. DOI: https://doi.org/10.1021/pr201070k
155. Goldman R, Ressom HW, Varghese RS, et al. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res 2009;15:1808-13. DOI: https://doi.org/10.1158/1078-0432.CCR-07-5261
156. Christiansen MN, Chick J, Lee L, et al. Cell surface protein glycosylation in cancer. Proteomics 2014;14:525-46. DOI: https://doi.org/10.1002/pmic.201300387
157. Eggermont L, Lumen N, Van Praet C, et al. A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer. Biochim Biophys Acta Rev Cancer 2025;1880:189239. DOI: https://doi.org/10.1016/j.bbcan.2024.189239
158. Abd-El-Halim YM, El Kaoutari A, Silvy F, et al. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. eBioMedicine 2021;71:103541. DOI: https://doi.org/10.1016/j.ebiom.2021.103541
159. Humphries MJ, Matsumoto K, White SL, et al. Augmentation of murine natural killer cell activity by swainsonine, a new antimetastatic immunomodulator. Cancer Res 1988;48:1410-5.
160. Dennis JW. Effects of swainsonine and polyinosinic:polycytidylic acid on murine tumor cell growth and metastasis. Cancer Res 1986;46:5131-6.
161. Galustian C, Foulds S, Dye JF, Guillou PJ. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity. Immunopharmacology 1994;27:165-72. DOI: https://doi.org/10.1016/0162-3109(94)90051-5
162. Wu J, Chen S, Liu H, et al. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. J Exp Clin Cancer Res 2018;37:272. DOI: https://doi.org/10.1186/s13046-018-0935-8
163. Ling Y-H, Li T, Perez-Soler R, Haigentz M. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol 2009;64:539-48. DOI: https://doi.org/10.1007/s00280-008-0902-8
164. Han X, Zhang X, Li H, et al. Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo. Oncotarget 2015;6:38912-25. DOI: https://doi.org/10.18632/oncotarget.5334
165. Guo X, Meng Y, Sheng X, et al. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway. Anticancer Drugs 2017;28:66-74. DOI: https://doi.org/10.1097/CAD.0000000000000431
166. Wang Y, Zhang L, He Z, et al. Tunicamycin induces ER stress and inhibits tumorigenesis of head and neck cancer cells by inhibiting N-glycosylation. Am J Transl Res 2020;12:541-50.
167. Nakano T, Matsui T, Ota T. Benzyl-alpha-GalNAc inhibits sialylation of O-glycosidic sugar chains on CD44 and enhances experimental metastatic capacity in B16BL6 melanoma cells. Anticancer Res 1996;16:3577-84.
168. Kojima N, Handa K, Newman W, Hakomori S. Inhibition of selectin-dependent tumor cell adhesion to endothelial cells and platelets by blocking O-glycosylation of these cells. Biochem Biophys Res Commun 1992;182:1288-95. DOI: https://doi.org/10.1016/0006-291X(92)91872-N
169. Gouyer V, Leteurtre E, Delmotte P, et al. Differential effect of GalNAcalpha-O-bn on intracellular trafficking in enterocytic HT-29 and Caco-2 cells: correlation with the glycosyltransferase expression pattern. J Cell Sci 2001;114:1455-71. DOI: https://doi.org/10.1242/jcs.114.8.1455
170. Byrd JC, Dahiya R, Huang J, Kim YS. Inhibition of mucin synthesis by benzyl-alpha-GalNAc in KATO III gastric cancer and Caco-2 colon cancer cells. Eur J Cancer 1995;31A:1498-505. DOI: https://doi.org/10.1016/0959-8049(95)00248-H
171. Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol 2014;4:28. DOI: https://doi.org/10.3389/fonc.2014.00028
172. Palacios-Acedo AL, Mezouar S, Mège D, et al. P2RY12-inhibitors reduce cancer-associated thrombosis and tumor growth in pancreatic cancers. Front Oncol 2021;11;3536. DOI: https://doi.org/10.3389/fonc.2021.704945
173. Sarantis P, Karamouzis MV. The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer. Thromb Res 2022;213:S120-6. DOI: https://doi.org/10.1016/j.thromres.2022.02.004
174. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primer 2022;8:11. DOI: https://doi.org/10.1038/s41572-022-00336-y
175. Takano K, Yukiura M, Takahashi K, et al. DS-3939a: a TA-MUC1-directed antibody-drug conjugate with broad antitumor activity. Mol Cancer Ther 2026;25:7-20. DOI: https://doi.org/10.1158/1535-7163.MCT-24-0666
176. Grewal US, Kurzrock R. Mucin-1: a promising pan-cancer therapeutic target. NPJ Precis Oncol 2025;9:218. DOI: https://doi.org/10.1038/s41698-025-01016-2
How to Cite
1.
Langiu M, Dubois C, Panicot-Dubois L. Platelet-driven remodeling of cancer cell glycoproteins fuels inflammation and metastasis. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/444
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
